


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Non-Fee Amendment, Assistant Commissioner for Patents, Washington, D.C. 20231 on December 10, 1999.
By: Nancy L. Glynn
Printed: Nancy L. Glynn



cket No.: PF-0148-2 DIV

RECEIVED

DEC 14 1999

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: HUMAN PYROPHOSPHATASE

Serial No.: 09/415,540

Filing Date: October 8, 1999

Examiner: Slobodyansky, E.

Group Art 1652

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
 2. Response to Restriction Requirement (4 pp., in duplicate);
- The fee has been calculated as shown below.

Claims	Claims After Amendment	-	Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate	Additional Fee(s)
Total Claims	6	-	20	=	0	\$18	\$0
Indep. Claims	2	-	3	=	0	\$78	\$0
First Presentation of Multiple Dependent Claim						+\$260	\$0

TOTAL \$ 0

☒ No additional fee is required.
☐ Please charge Incyte Pharmaceuticals, Inc. Deposit
Account No. 09-0108 the amount of \$

The Commissioner is hereby authorized to charge any additional fees required under 37.CFR 1.16 and 1.17, or credit overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


INCYTE PHARMACEUTICALS, INC.

Date: 10 December 1999

Diana Hamlet-Cox
Diana Hamlet-Cox, Ph.D.
Reg. No. 33,302

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 845-4639 Fax: (650) 849-8886

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box Non-Fee Amendment, Assistant Commissioner for Patents, Washington, D.C. 20231 on December 10, 1999.
 By: Nancy L. Glynn
 Printed: Nancy L. Glynn



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title: HUMAN PYROPHOSPHATASE

Serial No.: 09/415,540

Filing Date: October 8, 1999

Examiner: E. Slobodyansky

Group Art Unit: 1652

Box Non-Fee Amendment
 Assistant Commissioner for Patents
 Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121

Sir:

This is in response to the Restriction Requirement mailed November 12, 1999 in the above-referenced application.

Please amend the application for the above-referenced as follows:

IN THE CLAIMS:

Please cancel claim 17, without prejudice or disclaimer.

Please amend the claims as follows:

1. (Once Amended.) A substantially purified [human pyrophosphatase (HPYP)] polypeptide comprising [the] an amino acid sequence selected from the group consisting of
- a) an amino acid sequence of SEQ ID NO:1 [or fragments thereof],
 - b) a naturally-occurring amino acid sequence having at least 90% sequence identity to the sequence of SEQ ID NO:1,